By

Kshithija KJ Mulam

29
Jun
2020

Q&A with Regeneron SVP David Weinreich on Therapeutic Neutralizing Antibodies

Public discussion about the role of biotech and pharma in the pandemic tends to focus on one of two areas. Vaccines are the great hope, and occupy center stage. Gilead’s remdesivir has captured considerable attention, largely by being the first approved drug for COVID-19, despite offering a limited benefit for hospitalized patients. Off in the periphery of the public mind...
Read More
2
Jun
2020

Puretech Focuses on the Long-Term Lung Complications in COVID-19 Survivors

All eyes are on the healthcare industry as biotech and pharmaceutical companies race like never before to develop antiviral treatments and vaccines to curtail the immediate and most severe effects of contracting the virus. However, as new cases and unforeseen symptoms emerge, some scientists are shifting their focus to the extended repercussions of patients who survived their brush with COVID-19....
Read More